Navigation Links
European Commission Approves DuPont Tender Offer to Acquire Danisco
Date:4/5/2011

COPENHAGEN, Denmark, April 5, 2011 /PRNewswire/ -- The European Commission (EC) has approved, under the European Union Merger Regulation, the tender offer by DuPont Denmark Holding ApS to acquire all of the outstanding shares of Danisco at a price of DKK 665 in cash per share. DuPont Denmark Holding ApS is a wholly owned and fully controlled subsidiary of DuPont (NYSE: DD).

"We are pleased to have achieved one of the last important milestones in the pending acquisition of Danisco," said DuPont Chair and CEO Ellen Kullman. "Only Chinese approval now remains as a regulatory condition of closing. We remain confident that Danisco shareholders will follow their Board's recommendation to accept our premium cash offer and the transaction will be completed later this month."

The EC approval satisfies another major condition of the tender offer.  Competition approval has already been obtained in the United States and similar regulatory approval in China is progressing.  The offer period ends on April 29, 2011, at 11 p.m. CEST (5 p.m. EDT), unless further extended as described in the offer document.  

All terms and conditions of the offer are described in the offer document, which is available free of charge at www.dupontanddanisco.com or on the Danisco website at www.danisco.com with a copy of the statement of the board of directors of Danisco A/S Concerning the Voluntary Recommended Public Offer. 

DuPont (www.dupont.com) is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 90 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

This news release does not constitute an offer or invitation to purchase any securities or a solicitation of an offer to buy any securities, pursuant to the tender offer or otherwise. The tender offer is being made solely by means of an Offer Document and the documents accompanying the Offer Document, which contain the full terms and conditions of the tender offer, including details of how the tender offer may be accepted. Danisco A/S shareholders are advised to read the Offer Document and the related documents when they are sent to them because they contain important information.

Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products; and severe weather events that cause business interruptions, including plant and power outages, or disruptions in supplier and customer operations. Risks and uncertainties relating to the acquisition that could cause the actual results to differ from expectations contemplated by forward looking statements include: uncertainties as to the timing of the tender offer; uncertainties as to how many Danisco shares will be tendered in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; if the tender offer is completed, failure to achieve the expected benefits of the proposed acquisition. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information. 


'/>"/>
SOURCE DuPont
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
2. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
3. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
4. ApoA-I Data Presented at European Society of Cardiology Congress
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Kuvan Receives Positive Opinion From CHMP for European Approval
7. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
8. Elseviers PharmaPendium(TM) Adds European Medicines Agency (EMEA) Documents
9. European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
10. PRA International Addresses Sponsor-CRO Partnering Strategies at European Partnerships in Clinical Trials Congress
11. Oslo and Toulouse Cancer Clusters Join Forces to Drive European Cancer Research Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... IN (PRWEB) , ... May 31, 2016 , ... The ... Model Aviation Museum that will be on display Memorial Day through Labor Day 2016. ... Henry Chaffee, and Clark Chaffee. , Bill Chaffee won first place for Senior ...
(Date:5/27/2016)... Jersey and READING, ... -- Indegene ( http://www.indegene.com ), ... marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen und ... bekannter weltweiter Anbieter von innovativen wissenschaftlichen Support-Services ... des Starts von IntraScience heute den Ausbau ...
(Date:5/26/2016)... , May 26, 2016 Despite ... see value in this space. Today,s pre-market research on ActiveWallSt.com ... Radius Health Inc. (NASDAQ: RDUS ), Cerus Corp. ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... technical briefings at: http://www.activewallst.com/ ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of ... 2016 in San Francisco. Located at booth number 7301, representatives from the Thai ... and discuss the Thai biotechnology and life sciences sector. , Deputy Secretary ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):